VISTAGEN THERAPEUTICS, INC. (VTGN)

Every figure this model derived for VTGN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquireProductiveAssets 2024-03-31
cash 31,730,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 34,310,000 AssetsCurrent 2026-06-30
current liabilities 11,192,000 LiabilitiesCurrent 2026-06-30
equity 24,481,000 StockholdersEquity 2026-06-30
interest expense 27,000 InterestPaidNet 2026-06-30
ocf -62,297,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 2,502,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 4,072,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VTGN on one particular measure came for.

RatioValue
current ratio3.13
current ratio reported3.07
deferred revenue growth-90.69
dilution pct23.33
fcf margin-2489.89
interest cover-2580.15
revenue growth287.31
revenue growth per share214.05
rule of 40-2497.03
sbc pct revenue162.75

What to be careful about

What this model itself distrusts about VTGN's figures. Written by the derivation as it ran, not added afterwards.